Abbott to spend $2.9B on Latin American drugmaker

(AP)—Abbott Laboratories will spend about $2.9 billion to broaden its reach in Latin America with the acquisition of branded generic drugmaker CFR Pharmaceuticals.

Abbott makes like Similac as well as and drugs. The North Chicago, Illinois, company said Friday the will expand its presence in several fast-growing markets, especially with branded generic drugs.

An Abbott spokesman said generic drugs with are preferred in many developing markets due to their reputation for quality and consistent supply.

CFR Pharmaceuticals, which is based in Chile, sells more than 1,000 products in 15 Latin American markets. Abbott expects the deal to add about $900 million in revenue in 2015, the first full year after it is completed.

Abbott will buy the holding company that indirectly owns about 73 percent of CFR and then will conduct a cash tender offer for the remaining shares. The deal value tops $3 billion when counting about $430 million in debt.

Abbott will use cash to pay for the deal, which will have no impact on its 2014 earnings forecast. The drugmaker expects to close the acquisition by the end of the third quarter.

Shares of Abbott closed at $39.24 on Thursday, which puts them up about 2 percent so far this year. The stock had advanced 31 cents to $39.55 Friday about 45 minutes before markets opened.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Smith & Nephew to buy ArthroCare in $1.5B deal

Feb 03, 2014

British medical technology company Smith & Nephew plans to buy U.S. medical device maker ArthroCare in a $1.5 billion deal that it says will strengthen its sports medicine business.

Recommended for you

Express Scripts turns to AbbVie in huge hepatitis C deal

11 hours ago

The nation's largest pharmacy benefits manager is throwing its weight into the fight over high-cost hepatitis C drugs with a coverage restriction that might ultimately lower prices and improve patient access ...

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.